Evolution of platinum resistance in high-grade serous ovarian cancer
View abstract on PubMed
Summary
This summary is machine-generated.High-grade serous ovarian cancer often relapses quickly after chemotherapy. This rapid relapse may stem from intrinsically resistant cancer cell subpopulations present from the start.
Area Of Science
- Oncology
- Cancer Biology
- Chemotherapy Resistance
Background
- High-grade serous ovarian cancer (HGSOC) is the leading cause of ovarian cancer mortality.
- HGSOC initially responds to platinum-based chemotherapy but frequently develops resistance and relapse.
- Relapse timing predicts response to subsequent platinum treatment, with <6 months indicating resistance.
Purpose Of The Study
- To explore the link between HGSOC relapse patterns and underlying molecular/cellular characteristics.
- To investigate if intrinsic resistance in cancer cell subpopulations drives rapid relapse and platinum resistance.
Main Methods
- This is a Personal View, discussing existing research and proposing a hypothesis.
- Analysis of patterns in response, relapse, and drug resistance development in HGSOC.
- Focus on the potential role of pre-existing resistant cell populations.
Main Results
- Relapse within 6 months of first-line therapy typically signifies platinum resistance.
- Relapse after 12 months suggests a higher likelihood of response to secondary platinum treatment.
- The study proposes that intrinsic resistance in minor cancer cell subpopulations is key.
Conclusions
- Rapid relapse and platinum resistance in HGSOC may be driven by intrinsically resistant cancer cell subpopulations.
- Understanding these subpopulations could lead to novel therapeutic strategies for resistant ovarian cancer.
- Further research into the molecular basis of intrinsic resistance is warranted.